Business Wire

CA-NETAPP

7.6.2022 14:02:37 CEST | Business Wire | Press release

Share
NetApp Simplifies Hybrid Cloud Operations, Protects Against Ransomware Threats and Helps Accelerate VMware Workload Transitions to the Cloud

NetApp ® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced continued innovations and solutions to provide enterprises with more simplicity, more security and more flexibility for their hybrid multicloud environments.

These new capabilities include improved ransomware protection, hybrid cloud storage in a single subscription, unified management in a single user interface, and close collaboration with VMware to help transition workloads to the cloud.

As enterprises acquire public cloud services to augment their existing on-premises data centers, these combined infrastructures become more disparate, inconsistent and fragmented over time. These multicloud silos are inherently more complex to manage due to dealing with multiple disparate environments.

Today, NetApp is delivering a unified and consistent hybrid multicloud experience, allowing customers to run and manage a single platform that spans from on-premises to the world’s biggest public clouds.

“As organizations today explore the promise of hybrid multicloud environments, they are keen to avoid complexity, security, and cost efficiency challenges,” said Ronen Schwartz, senior vice president, Cloud Volumes Service at NetApp. “With NetApp’s simplified management and consumption experience, organizations can enjoy improved security, manageability, speed of operations, and cost savings - ultimately allowing them to be more responsive to the growing needs of their business by delivering capabilities faster, and keeping data available and protected no matter where it lives.”

Simple, secure, and flexible enhancements to NetApp’s hybrid cloud portfolio include:

Industry-Leading Hybrid Cloud Simplicity Experience

By delivering everything "as a service," NetApp simplifies and optimizes hybrid cloud environments with new capabilities, including:

  • Hybrid cloud Storage-as-a-Service (STaaS) in a single, flexible subscription with Keystone. Organizations can flexibly move workloads to and from the cloud in a single contract.
  • In addition to managing and monitoring data storage, protection, governance and tiering across multicloud environments, Cloud Manager can now manage Keystone services, track software licenses, monitor infrastructure health and provide proactive recommendations that optimize costs and data protection with automated actions.

"Organizations today are looking for flexibility both on-premises as well as across cloud providers and are investing in as-a-service consumption models to help achieve this," said Scott Sinclair, practice director at ESG. "NetApp's approach with Keystone is targeted at that need; offering hybrid cloud simplicity and flexibility that allows users to accelerate their IT objectives with management, orchestration, and billing wrapped into a single subscription and experience. Keystone's transferable subscription model also supports future cloud migration planning to any major cloud provider, with enterprise-level storage capability and integrated data protection."

Cyber Resilience for Today’s Hybrid Cloud

The rise of ransomware over the past few years is a growing problem for enterprises. IDC’s 2021 Ransomware Study: Where You Are Matters! 1 found that more than one third of organizations worldwide have experienced a ransomware attack or breach that blocked access to systems or data in the 12 months prior.

With NetApp’s new, powerful, built-in cyber resilience capabilities that include anti-ransomware, data protection and security - organizations can mitigate unauthorized user access and threats to data from ransomware attacks. Customers can protect a multitude of workloads, enterprise apps, virtualized workloads and modern containerized applications against security breaches, quickly detect attacks and rapidly recover data before experiencing any impact to operations.

Accelerating Enterprise Cloud Transformation –

NetApp is empowering customers to “modernize to the cloud” using a supplemental datastore for data-intensive, storage demanding workloads running in a single or across multicloud environments. NetApp is the only cloud storage service provider today to be certified and become supported for use as an external supplemental datastore for VMware Cloud environments running in the largest public clouds.

“Organizations across all industries rely on the combination of VMware and NetApp as the platform of choice for delivering business-critical workloads,” said Narayan Bharadwaj, vice president of Cloud Solutions at VMware. “NetApp is now able to deliver the same levels of enterprise-class data management that our mutual customers have enjoyed for decades on-premises to workloads running in any of the major public clouds.”

Additional Resources:

About NetApp

NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

1 IDC's 2021 Ransomware Study: Where You Are Matters! (IDC #US US48093721) July 2021

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye